| Title: |
The Omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers. |
| Alternate Title: |
Omicron en México: protección vacunal contra la progresión a Covid-19 grave en trabajadores infectados por SARS-CoV-2. |
| Authors: |
Hernández-Ávila, Mauricio1 mauricio.hernandeza@imss.gob.mx, Ivan Vieyra-Romero, Waldo1, Gutiérrez-Díaz, Héctor1, Zepeda-Tello, Rodrigo2, Alpuche-Aranda, Celia3, Eugenio Hernández-Ávila, Juan3, Barros-Sierra, David1, Tamayo-Ortiz, Marcela2, Duque-Molina, Celida1, Barrientos-Gutiérrez, Tonatiuh3, Carnalla-Cortés, Martha3, Dyer-Leal, Dwight4, López-Ridaura, Ruy4, López Gatell-Ramírez, Hugo4 |
| Source: |
Salud Pública de México. ene-feb2024, Vol. 66 Issue 1, p85-94. 10p. |
| Subject Terms: |
*COVID-19, *Disability insurance claims, *COVID-19 vaccines, SARS-CoV-2 Omicron variant, Poisson regression |
| Geographic Terms: |
Mexico, Mexico (Mexico : State) |
| Company/Entity: |
AstraZeneca PLC AZN |
| Abstract (English): |
Objective. To assess the effectiveness of seven Covid-19 vaccines in preventing disease progression (DP) using data from national private sector workers during the Omicron wave in Mexico from January 2 to March 5, 2022. Materials and methods. This study employed an administrative retrospective cohort design, analyzing DP (hospitalization or death due to respiratory disease) among workers who filed a respiratory short-term disability claim and tested positive for SARS-CoV-2. Risk ratios (RRadj) were estimated using Poisson regression models adjusted for various factors. Results. Vaccinated individuals had a lower risk of hospitalization and death compared with unvaccinated individuals. The overall RRadj for hospitalization and death were 0.36 (95%CI 0.32, 0.41) and 0.24 (0.17, 0.33), respectively. When evaluating workvaccines individually, the RRadj for hospitalization were as follows Pfizer BioNTech 0.27 (95%CI 0.22, 0.33), Moderna 0.29 (95%CI 0.15, 0.57), Sinovac 0.32 (95%CI 0.25, 0.41), AstraZeneca 0.39 (95%CI 0.34, 0.46), Sputnik 0.39 (95%CI 0.28, 0.53), CanSino 0.41 (95%CI 0.24, 0.7), and Janssen 0.53 (95%CI 0.39, 0.72). The RRadj for death were as follows: Pfizer BioNTech 0.12 (95%CI 0.07, 0.19), Sputnik 0.15 (95%CI 0.06, 0.38), Sinovac 0.29 (95%CI 0.16, 0.53), AstraZeneca 0.30 (95%CI 0.20, 0.44), CanSino 0.38 (95%CI 0.1, 1.4), and Janssen 0.50 (95%CI 0.26, 0.97). Conclusion. Covid-19 vaccines significantly reduced the risk of severe disease during the Omicron wave in Mexico. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
Objetivo. Evaluar la protección de siete vacunas Covid-19 contra la progresión de la enfermedad (PE) utilizando datos de trabajadores del sector privado durante el pico de transmisión Omicron del 2 de enero al 5 de marzo de 2022 en México. Material y métodos. Cohorte administrativa retrospectiva, analizando PE (hospitalización o muerte por enfermedad respiratoria) entre trabajadores que registraron una incapacidad temporal de trabajo por enfermedad respiratoria y fueron positivos a SARS-CoV-2. Se estimaron razones de riesgo (RRadj) mediante modelos de regresión de Poisson ajustados. Resultados. Los individuos vacunados tuvieron menor riesgo de hospitalización y muerte en comparación con los no vacunados. Los RRadj globales de hospitalización y muerte fueron 0.36 (IC95% 0.32,0.41) y 0.24 (0.17,0.33), respectivamente. Por vacuna, RRadj de hospitalización: Pfizer BioNTech 0.27 (IC95% 0.22,0.33), Moderna 0.29 (IC95% 0.15,0.57), Sinovac 0.32 (IC95% 0.25,0.41), AstraZeneca 0.39 (IC95% 0.34,0.46), Sputnik 0.39 (IC95% 0.28,0.53), CanSino 0.41 (IC95% 0.24,0.7), Janssen 0.53 (IC95% 0.39,0.72). RRadj de muerte: Pfizer BioNTech 0.12 (IC95% 0.07,0.19), Sputnik 0.15 (IC95% 0.06,0.38), Sinovac 0.29 (IC95% 0.16,0.53), AstraZeneca 0.30 (IC95% 0.20,0.44), CanSino 0.38 (IC95% 0.1,1.4), Janssen 0.50 (IC95% 0.26,0.97). Conclusión. Las vacunas Covid-19 redujeron significativamente el riesgo de enfermedad grave durante el pico de transmisión Omicron en México. [ABSTRACT FROM AUTHOR] |
|
Copyright of Salud Pública de México is the property of Instituto Nacional de Salud Publica and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Business Source Complete |
